BioNTech Results Presentation Deck
Significant newsflow expected over next 12-18 months
Indication (Target)
mRNA
Others
Platform
Fix Vac
iNeST
Intratumoral Immunotherapy
RiboMabs
RiboCytokines
CAR-T Cells
Next-Gen CP Immunomodulators
TLR7 Ligand
Infectious and Rare Diseases
Candidate
BNT111
BNT112
BNT113
BNT114
RO7198457
(BNT122)
SAR441000
(BNT131)
BNT141
BNT142
BNT151
BNT152/153
BNT211
BNT311
BNT411
BNT161
BNT162
Advanced Melanoma
Prostate Cancer
HPV16+ H&N Cancer
Triple Negative Breast Cancer
1L Melanoma with CPI
Multiple ST (basket trial)
NSCLC (adjuvant)
undisclosed (adjuvant)
Solid tumors
(IL-12sc, IL-15sushi, GM-CSF, IFN a)
Multiple ST
Multiple ST (CD3+CLDN6)
Multiple ST (Optimized IL-2)
Multiple Solid Tumors (IL-7, IL-2)
Multiple ST (CLDN6)
Multiple ST (PD-L1x4-1BB)
Multiple ST (TLR7)
Influenza
COVID-19
Up to 10 Infectious Disease Indications
5 Rare Disease Indications
Expected data readout / update
Next milestones 3
Start Phase 2 with registrational potential in 2H 2020
Report Phase 1: publication upcoming
Start Phase 2 with registrational potential in 2H 2020
Data update Phase 1 in 2H 2020 4
Enrollment update in 2H 2020 1
Data update Phase 1/2 at AACR Virtual II in June
Start Phase 2 in 2H 2020
Start Phase 2 in 2H 2020
Data update Phase 1/2 in 2H 2020 ²
Start Phase 1 in 1H 2021
Start Phase 1 in 1H 2021
Start Phase 1 in 1H 2021
Start Phase 1 in 1H 2021
Start Phase 1/2 in 2H 2020
Data update Phase 1/2 in 2H 2020
Start Phase 1 in 2H 2020
Start first study in 1H 2021
Data update in June/July 2020
Start phase 1 in 1H 2021
Start first Phase 1 in 1H 2021
7
¹We expect this update to include an update on the ongoing study, including patient enrollment numbers, with full efficacy and safety data for an interim update expected in the second half of 2021; 2As the trial is sponsored and conducted by Sanofi, the timing of data updates is not under our control,
and is subject to change by Sanofi. ³Our expectations for timing of milestones beyond 2020 are premised on and subject to the achievement of earlier milestones on their expected timelines. Press releases will be issued once first patient has been dosed.
ST: solid tumors.
4BNT 122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional treatment; BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42);View entire presentation